



## REGENXBIO to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference

May 8, 2019 11:00 AM EDT

ROCKVILLE, Md., May 8, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV<sup>®</sup> Technology Platform, today announced it will present at the Bank of America Merrill Lynch 2019 Healthcare Conference on Wednesday, May 15, 2019, at the Encore Wynn Hotel, Las Vegas, NV:

**Fireside chat:** Wednesday, May 15, 2019, at 10:40 a.m. PDT (1:40 p.m. EDT)

**Gene Therapy Panel:** Wednesday, May 15, 2019, at 4:20 p.m. PDT (7:20 p.m. EDT)

A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at [www.regenxbio.com](http://www.regenxbio.com). An archived replay of the fireside chat webcast will be available on the same website for approximately 30 days following the presentation.

### About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy.

REGENXBIO's NAV<sup>®</sup> Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

### CONTACT:

#### Investors

Heather Savelle, 212-600-1902

[heather@argotpartners.com](mailto:heather@argotpartners.com)

#### Media

David Rosen, 212-600-1902

[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)



 View original content to download multimedia: <http://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-bank-of-america-merrill-lynch-2019-healthcare-conference-300845832.html>

SOURCE REGENXBIO Inc.